Australia-based biotech Cartherics and CDMO Catalent have signed an amended commercial license agreement enabling the use of Catalent’s cGMP‑compliant induced pluripotent stem cells (iPSC) line for the manufacture and commercialization of Cartherics’ iPSC-derived CAR-NK cell therapies.
The agreement supports Cartherics’ mission to develop immune cell therapy products for the treatment of cancer and endometriosis.
Per the deal, Cartherics is granted rights to develop and commercialize multiple product candidates derived from a Catalent off-the-shelf cGMP iPSC line, including its lead CAR‑NK cell product, CTH‑401. Cartherics has already obtained approval from the U.S. FDA for use of the licensed iPSC line as the starting cell for generation of CTH‑401. Together, the two companies have also demonstrated full compatibility between CTH-401 and Catalent’s iPSC-NK manufacturing platform.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!